Adverum Biotechnologies (ADVM) News Today $6.17 -0.08 (-1.28%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Truist Financial Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)November 20 at 11:26 AM | markets.businessinsider.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 5.9%November 20 at 2:39 AM | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Adverum Biotechnologies in a research note on Tuesday.November 19 at 8:22 AM | marketbeat.comAdverum Biotechnologies reports results of two trials of Ixo-vec in AMDNovember 18 at 10:32 PM | markets.businessinsider.comBuy Rating on Adverum Biotechnologies: Ixo-vec’s Promising Potential in Transforming Wet AMD TreatmentNovember 18 at 10:32 PM | markets.businessinsider.comAdverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design ElementsNovember 18 at 5:32 PM | markets.businessinsider.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Decreases By 5.9%Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 1,600,000 shares, a drop of 5.9% from the October 15th total of 1,700,000 shares. Currently, 13.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 184,100 shares, the short-interest ratio is currently 8.7 days.November 18 at 2:19 AM | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recoNovember 16, 2024 | marketbeat.comAdverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design ElementsNovember 15, 2024 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Acquired by BML Capital Management LLCBML Capital Management LLC boosted its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 15.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,268,064 shares of the biotechnology company's stock aNovember 12, 2024 | marketbeat.comChardan Capital Has Pessimistic View of ADVM FY2024 EarningsAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Analysts at Chardan Capital reduced their FY2024 earnings estimates for shares of Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, November 5th. Chardan Capital analyst D. Gataulin now expects thatNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for ADVM FY2024 Earnings?Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst M. Caufield now expects thatNovember 7, 2024 | marketbeat.comRBC Capital Sticks to Their Hold Rating for Adverum Biotechnologies (ADVM)November 7, 2024 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada cut their target price on Adverum Biotechnologies from $12.00 to $10.00 and set a "sector perform" rating for the company in a research note on Tuesday.November 5, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPSAdverum Biotechnologies (NASDAQ:ADVM - Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($1.30) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.10). The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.50 million.November 5, 2024 | marketbeat.comAdverum Biotechnologies (ADVM) Gets a Buy from TD CowenNovember 5, 2024 | markets.businessinsider.comAdverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated MilestonesNovember 4, 2024 | globenewswire.comAssenagon Asset Management S.A. Cuts Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Assenagon Asset Management S.A. reduced its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 96.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,413 shares of the biNovember 4, 2024 | marketbeat.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Increases By 14.9%Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,700,000 shares, a growth of 14.9% from the September 30th total of 1,480,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 8.4 days. Currently, 12.0% of the shares of the stock are sold short.October 29, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from AnalystsAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy raOctober 22, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)October 17, 2024 | markets.businessinsider.comPromising Potential of ADAR RNA Editing Fuels Buy RatingOctober 17, 2024 | markets.businessinsider.comAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal ProgramOctober 16, 2024 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 9.2% in SeptemberAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,480,000 shares, a decline of 9.2% from the September 15th total of 1,630,000 shares. Based on an average trading volume of 279,100 shares, the days-to-cover ratio is presently 5.3 days. Currently, 10.5% of the company's shares are sold short.October 15, 2024 | marketbeat.comDimensional Fund Advisors LP Boosts Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Dimensional Fund Advisors LP increased its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 741.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 223,427 shares of the biOctober 13, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Stock Position Increased by Squarepoint Ops LLCSquarepoint Ops LLC boosted its position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 301.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 108,978 shares of the biotechnology company's stocOctober 8, 2024 | marketbeat.comMarshall Wace LLP Increases Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Marshall Wace LLP grew its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 52.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 204,619 shares of the biotechnologyOctober 7, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comLogos Global Management LP Has $2.86 Million Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Logos Global Management LP cut its position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 72.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 416,666 shares of the biotechnology compaOctober 1, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)September 27, 2024 | markets.businessinsider.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Average Rating of "Moderate Buy" by BrokeragesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommeSeptember 27, 2024 | marketbeat.comLogos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Logos Global Management LP cut its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 72.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 416,666 shares of the biotechnology company's stock aSeptember 24, 2024 | marketbeat.comTruist Financial Issues a Buy Rating on Adverum Biotechnologies (ADVM)September 21, 2024 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Stock Passes Below 200-Day Moving Average of $9.52Adverum Biotechnologies (NASDAQ:ADVM) Shares Cross Below 200-Day Moving Average of $9.52September 18, 2024 | marketbeat.comAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2024 | globenewswire.comAdverum Biotechnologies to Participate in Upcoming Fall Investor ConferencesSeptember 4, 2024 | globenewswire.comAdverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Above Fifty Day Moving Average of $7.31Adverum Biotechnologies (NASDAQ:ADVM) Stock Passes Above 50 Day Moving Average of $7.31August 28, 2024 | marketbeat.comAdverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial StabilityAugust 21, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Has $4.24 Million Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Assenagon Asset Management S.A. raised its holdings in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 72.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 617August 20, 2024 | marketbeat.comChardan Capital Research Analysts Boost Earnings Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Analysts at Chardan Capital raised their FY2024 earnings per share estimates for shares of Adverum Biotechnologies in a research note issued on Tuesday, August 13th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnolAugust 16, 2024 | marketbeat.comAdverum Biotechnologies, Inc. to Post FY2025 Earnings of ($4.31) Per Share, Chardan Capital Forecasts (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Adverum Biotechnologies in a note issued to investors on Tuesday, August 13th. Chardan Capital analyst D. Gataulin expects that theAugust 15, 2024 | marketbeat.comBuy Rating for Adverum Biotechnologies Based on Promising Ixo-Vec Therapy and Strategic Growth OpportunitiesAugust 14, 2024 | markets.businessinsider.comAdverum Biotechnologies’ Ixo-vec Shows Promise in Wet AMD Treatment: Analyst Reiterates Buy Rating and $30 Price TargetAugust 14, 2024 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Price Target Lowered to $40.00 at Truist FinancialTruist Financial lowered their target price on shares of Adverum Biotechnologies from $60.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday.August 14, 2024 | marketbeat.comVanguard Group Inc. Sells 3,281,883 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Vanguard Group Inc. decreased its holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 78.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 907,151 shares of the biotechnology company's stock after selliAugust 14, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $12.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada cut their price objective on shares of Adverum Biotechnologies from $15.00 to $12.00 and set a "sector perform" rating for the company in a research report on Tuesday.August 13, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Issues Earnings Results, Beats Estimates By $0.58 EPSAdverum Biotechnologies (NASDAQ:ADVM - Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.58.August 13, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Buy" from BrokeragesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has received an average rating of "Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year pricAugust 8, 2024 | marketbeat.comTruist Financial Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)August 3, 2024 | markets.businessinsider.comAdverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 2, 2024 | globenewswire.com Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. ADVM Media Mentions By Week ADVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼0.640.45▲Average Medical News Sentiment ADVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼112▲ADVM Articles Average Week Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BDTX News CHRS News CCCC News SGMO News PRTC News TERN News MREO News ARCT News YMAB News ZVRA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
